For Whom the Cell Tolls? Intratumoral Treatment Links Innate and Adaptive Immunity

Intratumoral immunotherapy can potentially modulate the tumor microenvironment (TME) and potentiate the effects of concomitant or sequential systemic immunotherapies. Intratumoral administration of different Toll-like receptor agonists, including TLR4, can potentiate these effects through innate and adaptive immunity connection.

See related article by Bhatia et al., p. 1185

http://bit.ly/2GJKCov